Spyre Therapeutics, Inc. (SYRE) Total liabilities 2016–2025
Spyre Therapeutics, Inc. (SYRE) total liabilities at each fiscal year-end, per SEC filings.
$62.5MFY2025 · since FY2016: $4.1M → $62.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $62.5M | -31.0% |
| FY2024 | $90.7M | +23.7% |
| FY2023 | $73.3M | +251.7% |
| FY2022 | $20.8M | -19.8% |
| FY2021 | $26.0M | +19.3% |
| FY2020 | $21.8M | -5.7% |
| FY2019 | $23.1M | +124.1% |
| FY2018 | $10.3M | +79.6% |
| FY2017 | $5.7M | +40.1% |
| FY2016 | $4.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice